country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-181934

Copy Link Print Information

ClpP activator-2

ClpP activator-2 (Compound GU18) is a ClpP activator with a K_d of 5.01 μM for HsClpP. ClpP activator-2 enhances the proteolytic activity of HsClpP and promotes the degradation of α-casein by HsClpP, with an EC₅₀ of 1.09 μM. ClpP activator-2 induces the accumulation of mitochondrial reactive oxygen species (ROS), leading to damage to mitochondrial structure and function. ClpP activator-2 exhibits significant in vivo anti-multiple myeloma activity.

For research use only. We do not sell to patients.

CAS No.: 3036751-71-7
Formula: C₂₂H₁₉Cl₂F₃N₄O
Molecular Weight:483.31

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

ClpP activator-2 Chemical Structure

CAS No.: 3036751-71-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
MV4-11	IC₅₀	10 μM Compound: 7e	Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay	[PMID: 38620134]

In Vitro

ClpP activator-2 potently activates purified HsClpP with an EC₅₀ of 0.54 ± 0.12 μM^[1].
ClpP activator-2 (2 h) promotes the degradation of α-casein by HsClpP, with an EC₅₀ of 1.09 ± 0.08 μM^[1].
ClpP activator-2 binds to purified HsClpP, and its dissociation constant K_d is determined as 5.01 ± 1.05 μM by ITC^[1].
ClpP activator-2 (0.45 μM; 24 h) causes significant mitochondrial ultrastructural damage to AMO.1 MM cells after treatment at 0.45 μM for 24 h^[1].
ClpP activator-2 (0.15-0.6 μM; 48 h) promotes the accumulation of mitochondrial reactive oxygen species (ROS) in AMO.1 and ARP1 multiple myeloma (MM) cells in a concentration-dependent manner after 48 h of treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Human multiple myeloma cell lines AMO.1, ARP1
Concentration:

Gradient concentrations
Incubation Time:

24 h, 48 h, 72 h
Result:

Reduced cell viability in a time- and concentration-dependent manner.
For AMO.1 cells, reached IC₅₀ values of 1.30 ± 0.08 μM (24 h), 0.68 ± 0.03 μM (48 h), and 0.08 ± 0.01 μM (72 h).
For ARP1 cells, reached IC₅₀ values of 1.81 ± 0.14 μM (24 h), 0.86 ± 0.08 μM (48 h), and 0.21 ± 0.02 μM (72 h).

Cell Cycle Analysis^[1]

Cell Line:

Human multiple myeloma cell lines AMO.1, ARP1
Concentration:

0.15-0.6 μM
Incubation Time:

24 h
Result:

Induced dose-dependent G1 phase.

Apoptosis Analysis^[1]

Cell Line:

Human multiple myeloma cell lines AMO.1, ARP1
Concentration:

0.15-0.6 μM (apoptosis assay); 0.45 μM (Western blotting)
Incubation Time:

24 h, 48 h, 72 h (apoptosis assay); 48 h (Western blotting)
Result:

Induced time- and concentration-dependent apoptosis, with 95% of AMO.1 cells and 73.8% of ARP1 cells apoptotic after 72 h of 0.6 μM treatment.
Upregulated cleaved caspase-3.

Parmacokinetics

Species	Dose	Route	C_max	T_1/2	Bioavailability
Rat^[1]	5 mg/kg	i.v.	16733.33 ng/mL	3.854 h	38.9 %
Rat^[1]	10 mg/kg	p.o.	6050 ng/mL	3.198 h	/

In Vivo

ClpP activator-2 (5-30 mg/kg; i.p.; once every other day; 14 days) dose-dependently inhibits the tumor growth of multiple myeloma in NOD/SCID mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD/SCID (female, 6-8 weeks old, subcutaneous xenograft model)^[1]
Dosage:

5 mg/kg; 15 mg/kg; 30 mg/kg
Administration:

i.p.; every other day; 14 days
Result:

Achieved 56.7% tumor volume inhibition at 5 mg/kg.
Achieved 83.4% tumor volume inhibition at 15 mg/kg.
Achieved 91.4% tumor volume inhibition at 30 mg/kg.
Showed no treatment-related damage to major organs in the 30 mg/kg group compared to controls.

Chemical Information

CAS No. 3036751-71-7
Molecular Weight 483.31
Formula C₂₂H₁₉Cl₂F₃N₄O
SMILES

O=C1NC(NCC2=CC=C(C(F)(F)F)C=C2)=NC3=C1CN(CC3)CC4=CC(Cl)=C(Cl)C=C4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Liu X, et al. Discovery of 2-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d] pyrimidine derivatives as novel HsClpP activators for multiple myeloma therapy. Eur J Med Chem. Published online February 26, 2026. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

100 mg

Get Quote In-stock